Key Points
- Evan Kearns sold 65,000 shares of Cogent Biosciences on Dec. 26 at an average price of $38.70, generating $2.52 million and reducing his stake by 37.27% to 109,398 shares (worth ≈$4.23 million).
- Analysts are broadly positive: the consensus rating is a “Moderate Buy” with a $37.82 average target, while firms including JPMorgan, Leerink and HC Wainwright have raised targets (JPMorgan to $67, Leerink/HC Wainwright to $50) and multiple analysts carry Buy/Strong Buy ratings.
- Recent company/stock signals: Cogent reported Q results of (‑$0.50) EPS beating estimates by $0.04, the stock opened at $37.12 (down ~2.1%), has a market cap of $5.29 billion and a one‑year range of $3.72–$43.73.
Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) insider Evan Kearns sold 65,000 shares of the stock in a transaction on Friday, December 26th. The shares were sold at an average price of $38.70, for a total value of $2,515,500.00. Following the transaction, the insider directly owned 109,398 shares of the company's stock, valued at approximately $4,233,702.60. The trade was a 37.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Cogent Biosciences Stock Down 2.1%
COGT opened at $37.12 on Wednesday. Cogent Biosciences, Inc. has a one year low of $3.72 and a one year high of $43.73. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.38 and a current ratio of 6.38. The stock's fifty day moving average is $32.14 and its 200-day moving average is $19.03. The company has a market capitalization of $5.29 billion, a PE ratio of -22.63 and a beta of 0.49.
Cogent Biosciences (NASDAQ:COGT - Get Free Report) last announced its earnings results on Monday, November 3rd. The technology company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.04. On average, equities analysts predict that Cogent Biosciences, Inc. will post -2.42 EPS for the current fiscal year.
Hedge Funds Weigh In On Cogent Biosciences
Several institutional investors and hedge funds have recently added to or reduced their stakes in COGT. Osaic Holdings Inc. raised its stake in Cogent Biosciences by 41.4% during the 2nd quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company's stock valued at $33,000 after purchasing an additional 1,333 shares during the period. Strs Ohio purchased a new position in shares of Cogent Biosciences during the first quarter valued at $36,000. Ameritas Investment Partners Inc. raised its position in Cogent Biosciences by 16.6% during the second quarter. Ameritas Investment Partners Inc. now owns 10,839 shares of the technology company's stock valued at $78,000 after buying an additional 1,543 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Cogent Biosciences by 22.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,401 shares of the technology company's stock valued at $78,000 after buying an additional 1,003 shares during the period. Finally, CWM LLC lifted its stake in Cogent Biosciences by 25.3% in the 3rd quarter. CWM LLC now owns 5,582 shares of the technology company's stock worth $80,000 after acquiring an additional 1,126 shares in the last quarter.
Analysts Set New Price Targets
A number of research firms recently commented on COGT. Jefferies Financial Group reiterated a "buy" rating and issued a $48.00 target price on shares of Cogent Biosciences in a report on Monday, December 8th. Leerink Partners lifted their price target on shares of Cogent Biosciences from $18.00 to $50.00 and gave the stock an "outperform" rating in a research report on Monday, November 10th. Raymond James Financial initiated coverage on Cogent Biosciences in a report on Tuesday, September 2nd. They issued a "strong-buy" rating and a $30.00 price target on the stock. HC Wainwright raised their price objective on Cogent Biosciences from $21.00 to $50.00 and gave the stock a "buy" rating in a research note on Thursday, November 13th. Finally, JPMorgan Chase & Co. boosted their target price on Cogent Biosciences to $67.00 and gave the stock an "overweight" rating in a research report on Friday, December 19th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $37.82.
Check Out Our Latest Report on Cogent Biosciences
About Cogent Biosciences
(
Get Free Report)
Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.
The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
